Related Experiment Videos

Phosphatidylinositol 3-kinase/Akt activity regulates c-FLIP expression in tumor cells

D J Panka1, T Mano, T Suhara

  • 1Department of Hematology and Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA.

Insights

The phosphatidylinositol 3-kinase (PI3K)-Akt pathway, not MEK1, regulates FLICE-inhibitory protein (FLIP) in tumor cells. This pathway controls FLIP expression, impacting apoptosis resistance and offering potential therapeutic targets.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Signaling

Background:

  • FLICE-inhibitory protein (FLIP) inhibits apoptosis by blocking caspase-8 activation.
  • FLIP expression is linked to resistance against tumor necrosis factor (TNF) family-induced apoptosis and Fas-mediated cell death.
  • While MEK1 regulates FLIP in T cells, the pathways controlling FLIP in tumor cells remain unclear.

Purpose of the Study:

  • To investigate the roles of MAP kinase and phosphatidylinositol 3-kinase (PI3K) signaling pathways in regulating FLIP expression in tumor cells.

Main Methods:

  • Treatment of tumor cell lines with MEK1 inhibitor PD98059 and PI3K inhibitor LY294002.
  • Assessment of FLIP protein and mRNA levels, and Akt phosphorylation.
  • Utilized dominant-negative and constitutively active Akt adenoviral constructs to modulate Akt activity.

Main Results:

  • MEK1 inhibition only affected FLIP levels in a minority of tumor cell lines.
  • PI3K pathway disruption with LY294002 consistently reduced FLIP protein/mRNA and Akt phosphorylation across all tested cell lines.
  • Modulation of Akt activity via adenoviral constructs directly altered FLIP expression and Akt target phosphorylation (GSK-3).

Conclusions:

  • The PI3K-Akt pathway, rather than MEK1, is a key regulator of FLIP expression in tumor cells.
  • These findings identify FLIP as another apoptosis inhibitor regulated by the PI3K-Akt pathway, suggesting potential therapeutic implications.

Related Concept Videos